{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:59:52Z","timestamp":1788469192331,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17982-3","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:50:00Z","timestamp":1758883800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of novel disulfide-containing PD-1\/PD-L1 inhibitor with in vivo influenza therapeutic efficacy"],"prefix":"10.1038","volume":"15","author":[{"given":"Yoshiyuki","family":"Hirata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunobu","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Uesato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"17982_CR1","doi-asserted-by":"publisher","first-page":"19393","DOI":"10.18632\/oncotarget.5107","volume":"6","author":"X Sui","year":"2015","unstructured":"Sui, X. et al. The anticancer immune response of anti-PD-1\/PD-L1 and the genetic determinants of response to anti-PD-1\/PD-L1 antibodies in cancer patients. Oncotarget 6, 19393\u201319404 (2015).","journal-title":"Oncotarget"},{"key":"17982_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"17982_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"17982_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205\u2013214 (2015).","journal-title":"Cell"},{"key":"17982_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"17982_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561\u2013584 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"17982_CR7","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","volume":"21","author":"A Patnaik","year":"2015","unstructured":"Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti\u2013PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286\u20134293 (2015).","journal-title":"Clin. Cancer Res."},{"key":"17982_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","volume":"13","author":"DN Khalil","year":"2016","unstructured":"Khalil, D. N. et al. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273\u2013290 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"17982_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos, A. Development of immuno-oncology drugs\u2014From CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235\u2013247 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"17982_CR10","doi-asserted-by":"publisher","first-page":"e1365209","DOI":"10.1080\/2162402X.2017.1365209","volume":"7","author":"V Vanella","year":"2017","unstructured":"Vanella, V. et al. PD-L1 Inhibitors in the pipeline: Promise and progress. Oncoimmunology 7, e1365209 (2017).","journal-title":"Oncoimmunology"},{"key":"17982_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/med.21530","volume":"39","author":"J Yang","year":"2019","unstructured":"Yang, J. & Hu, L. Immunomodulators targeting the PD-1\/PD-L1 protein-protein interaction: From antibodies to small molecules. Med. Res. Rev. 39, 265\u2013301 (2019).","journal-title":"Med. Res. Rev."},{"key":"17982_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","volume":"30","author":"TH Patel","year":"2024","unstructured":"Patel, T. H. et al. FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin. Cancer Res. 30, 269\u2013273 (2024).","journal-title":"Clin. Cancer Res."},{"key":"17982_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller, N. et al. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity 57, 206\u2013222 (2024).","journal-title":"Immunity"},{"key":"17982_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L. et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol. Oncol. 16, 101 (2023).","journal-title":"J Hematol. Oncol."},{"key":"17982_CR15","doi-asserted-by":"publisher","first-page":"12916","DOI":"10.1128\/JVI.02423-13","volume":"87","author":"B McNally","year":"2013","unstructured":"McNally, B. et al. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. J. Virol. 87, 12916\u201312924 (2013).","journal-title":"J. Virol."},{"key":"17982_CR16","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.26512","volume":"93","author":"X Boumaza","year":"2023","unstructured":"Boumaza, X. et al. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. Ann. Neurol. 93, 257\u2013270 (2023).","journal-title":"Ann. Neurol."},{"key":"17982_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri.2017.112","volume":"18","author":"MN Wykes","year":"2018","unstructured":"Wykes, M. N. & Lewin, S. R. Immune checkpoint blockade in infectious diseases. Nat. Rev. Immunol. 18, 91\u2013104 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"17982_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12026-015-8680-y","volume":"64","author":"W Xiao","year":"2016","unstructured":"Xiao, W. et al. PD-1\/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. Immunol. Res. 64, 412\u2013423 (2016).","journal-title":"Immunol. Res."},{"key":"17982_CR19","doi-asserted-by":"publisher","first-page":"11740","DOI":"10.3390\/ijms231911740","volume":"23","author":"D Jarczak","year":"2022","unstructured":"Jarczak, D. & Nierhaus, A. Cytokine storm\u2014Definition, causes, and implications. Int. J. Mol. Sci. 23, 11740 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"17982_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4110\/in.2020.20.e9","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi, J. & Lee, S. Y. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune. Netw. 20, 1\u201321 (2020).","journal-title":"Immune. Netw."},{"key":"17982_CR21","doi-asserted-by":"publisher","first-page":"30323","DOI":"10.18632\/oncotarget.8730","volume":"7","author":"KM Zak","year":"2016","unstructured":"Zak, K. M. et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7, 30323\u201330335 (2016).","journal-title":"Oncotarget"},{"key":"17982_CR22","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","volume":"60","author":"K Guzik","year":"2017","unstructured":"Guzik, K. et al. Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. J. Med. Chem. 60, 5857\u20135867 (2017).","journal-title":"J. Med. Chem."},{"key":"17982_CR23","doi-asserted-by":"publisher","first-page":"72167","DOI":"10.18632\/oncotarget.20050","volume":"8","author":"L Skalniak","year":"2017","unstructured":"Skalniak, L. et al. Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget 8, 72167\u201372181 (2017).","journal-title":"Oncotarget"},{"key":"17982_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","volume":"27","author":"K Li","year":"2019","unstructured":"Li, K. & Tian, H. Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J. Drug Target. 27, 244\u2013256 (2019).","journal-title":"J. Drug Target."},{"key":"17982_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/molecules24112071","volume":"24","author":"K Guzik","year":"2019","unstructured":"Guzik, K. et al. Development of the inhibitors that target the PD-1\/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. Molecules 24, 2071 (2019).","journal-title":"Molecules"},{"key":"17982_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ab.2018.02.003","volume":"547","author":"Y Han","year":"2018","unstructured":"Han, Y. et al. PD-1\/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy. Anal. Biochem. 547, 52\u201356 (2018).","journal-title":"Anal. Biochem."},{"key":"17982_CR27","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","volume":"62","author":"S Basu","year":"2019","unstructured":"Basu, S. et al. Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein\u2013protein interaction. J. Med. Chem. 62, 7250\u20137263 (2019).","journal-title":"J. Med. Chem."},{"key":"17982_CR28","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.1021\/acs.jmedchem.1c00392","volume":"64","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Syntheses, biological evaluations, and mechanistic studies of benzo[c][1,2,5]oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity. J. Med. Chem. 64, 8391\u20138409 (2021).","journal-title":"J. Med. Chem."},{"key":"17982_CR29","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3390\/molecules24152804","volume":"24","author":"B Musielak","year":"2019","unstructured":"Musielak, B. et al. CA-170-A potent small-molecule PD-L1 inhibitor or not?. Molecules 24, 2804 (2019).","journal-title":"Molecules"},{"key":"17982_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","volume":"4","author":"PG Sasikumar","year":"2021","unstructured":"Sasikumar, P. G. et al. PD-1 Derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun. Biol. 4, 699 (2021).","journal-title":"Commun. Biol."},{"key":"17982_CR31","doi-asserted-by":"publisher","first-page":"135900","DOI":"10.1016\/j.molstruc.2023.135900","volume":"1289","author":"Q Geng","year":"2023","unstructured":"Geng, Q. et al. Synthesis and peliminary ealuation of ainophenol drivatives as mlecular glues bocking PD-1\/PD-L1 interaction. J. Mol. Struct. 1289, 135900 (2023).","journal-title":"J. Mol. Struct."},{"key":"17982_CR32","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.bmc.2016.03.021","volume":"24","author":"S Uesato","year":"2016","unstructured":"Uesato, S. et al. Discovery of new low-molecular-weight p53-mdmx disruptors and their anti-cancer activities. Bioorg. Med. Chem. 24, 1919\u20131926 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"17982_CR33","unstructured":"Chupak, L. S. & Zheng, X. Compounds useful as immunomodulators. WO2015034820A1 (2015)."},{"key":"17982_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona, S., Diamandis, E. P. & Blasutig, I. M. Cancer immunotherapy: The beginning of the end of cancer?. BMC Med. 14, 73 (2016).","journal-title":"BMC Med."},{"key":"17982_CR35","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1200\/EDBK_158712","volume":"35","author":"SJ Antonia","year":"2016","unstructured":"Antonia, S. J., Vansteenkiste, J. F. & Moon, E. Immunotherapy: Beyond anti-PD-1 and anti-PD-L1 therapies. Am. Soc. Clin. Oncol. Educ. Book 35, e450\u2013e458 (2016).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"17982_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/blood-2012-02-412510","volume":"120","author":"WJ Norde","year":"2012","unstructured":"Norde, W. J. et al. Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention. Blood 120, 728\u2013736 (2012).","journal-title":"Blood"},{"key":"17982_CR37","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/carcin\/bgy163","volume":"40","author":"Y Zhao","year":"2019","unstructured":"Zhao, Y. et al. Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. Carcinogenesis 40, 1132\u20131141 (2019).","journal-title":"Carcinogenesis"},{"key":"17982_CR38","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.vaccine.2019.02.055","volume":"37","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine 37, 2090\u20132098 (2019).","journal-title":"Vaccine"},{"key":"17982_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/intimm\/dxq049","volume":"22","author":"M Ghiotto","year":"2010","unstructured":"Ghiotto, M. et al. PD-L1 and PD-L2 Differ in their molecular mechanisms of interaction with PD-1. Int. Immunol. 22, 651\u2013660 (2010).","journal-title":"Int. Immunol."},{"key":"17982_CR40","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.str.2016.06.026","volume":"24","author":"R Pascolutti","year":"2016","unstructured":"Pascolutti, R. et al. Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant. Structure 24, 1719\u20131728 (2016).","journal-title":"Structure"},{"key":"17982_CR41","doi-asserted-by":"publisher","first-page":"12392","DOI":"10.1038\/s41598-019-48826-6","volume":"9","author":"A Ganesan","year":"2019","unstructured":"Ganesan, A. et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci. Rep. 9, 12392 (2019).","journal-title":"Sci. Rep."},{"key":"17982_CR42","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1039\/D0CE00211A","volume":"22","author":"IS Veljkovi\u0107","year":"2020","unstructured":"Veljkovi\u0107, I. S. et al. What is the preferred geometry of sulfur\u2013disulfide interactions?. CrystEngComm 22, 7262\u20137271 (2020).","journal-title":"CrystEngComm"},{"key":"17982_CR43","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2022.01.011","volume":"185","author":"AC Walls","year":"2022","unstructured":"Walls, A. C. et al. SARS-CoV-2 Breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 185, 872-880.E3 (2022).","journal-title":"Cell"},{"key":"17982_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/1348-0421.12316","volume":"59","author":"Y Tsurudome","year":"2015","unstructured":"Tsurudome, Y. et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: A Phase II, open-label, uncontrolled trial in Japan. Microbiol. Immunol. 59, 597\u2013604 (2015).","journal-title":"Microbiol. Immunol."},{"key":"17982_CR45","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.molonc.2015.12.012","volume":"10","author":"M Lienlaf","year":"2016","unstructured":"Lienlaf, M. et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol. 10, 735\u2013750 (2016).","journal-title":"Mol. Oncol."},{"key":"17982_CR46","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.2217\/imt-2020-0109","volume":"12","author":"L Gatto","year":"2020","unstructured":"Gatto, L. et al. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. Immunotherapy 12, 1111\u20131114 (2020).","journal-title":"Immunotherapy"},{"key":"17982_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2020.05.026","volume":"135","author":"SD Cosimo","year":"2020","unstructured":"Cosimo, S. D. et al. Immune checkpoint inhibitors: A physiology-driven approach to the treatment of coronavirus disease 2019. Eur. J. Cancer 135, 62\u201365 (2020).","journal-title":"Eur. J. Cancer"},{"key":"17982_CR48","doi-asserted-by":"publisher","first-page":"e001145","DOI":"10.1136\/jitc-2020-001145","volume":"8","author":"T Gambichler","year":"2020","unstructured":"Gambichler, T. et al. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J. Immunother. Cancer 8, e001145 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"17982_CR49","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.toxrep.2020.07.006","volume":"7","author":"CE Garner","year":"2020","unstructured":"Garner, C. E. et al. Disposition and metabolism of 2\u2019, 2\u2019-dithiobisbenzanilide in rodents following intravenous and oral administration and dermal application. Toxicol. Rep. 7, 883\u2013892 (2020).","journal-title":"Toxicol. Rep."},{"key":"17982_CR50","first-page":"386","volume":"33","author":"T Shibata","year":"2022","unstructured":"Shibata, T. Study on the effect of tire and road wear particles on the environment and human health. J. Mater. Cycles Waste Manage. 33, 386\u2013391 (2022).","journal-title":"J. Mater. Cycles Waste Manage."},{"key":"17982_CR51","doi-asserted-by":"publisher","first-page":"115002","DOI":"10.1016\/j.marpolbul.2023.115002","volume":"192","author":"UJ Maji","year":"2023","unstructured":"Maji, U. J. et al. Toxicological effects of tire rubber-derived 6PPD-quinone, a species-specific toxicant, and dithiobisbenzanilide (DTBBA) in the marine rotifer Brachionus koreanus. Mar. Pollut. Bull. 192, 115002 (2023).","journal-title":"Mar. Pollut. Bull."},{"key":"17982_CR52","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.scitotenv.2009.10.016","volume":"408","author":"ML Kreider","year":"2010","unstructured":"Kreider, M. L. et al. Physical and chemical characterization of tire-related particles: Comparison of particles generated using different methodologies. Sci. Total Environ. 408, 652\u2013659 (2010).","journal-title":"Sci. Total Environ."},{"key":"17982_CR53","first-page":"9223","volume":"47","author":"KM Unice","year":"2013","unstructured":"Unice, K. M., Kreider, M. L. & Panko, J. M. Comparison of tire and road wear particle concentrations in sediment for watersheds in France, Japan, and the United States by quantitative pyrolysis GC\/MS analysis. Environ. Sci. Technol. 47, 9223\u20139231 (2013).","journal-title":"Environ. Sci. Technol."},{"key":"17982_CR54","doi-asserted-by":"publisher","first-page":"23C","DOI":"10.1042\/bj0940023C","volume":"94","author":"NM Green","year":"1965","unstructured":"Green, N. M. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem. J. 94, 23C-24C (1965).","journal-title":"Biochem. J."},{"key":"17982_CR55","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.1021\/jf0721287","volume":"55","author":"Y Ohta","year":"2007","unstructured":"Ohta, Y. et al. In vivo anti-influenza virus activity of an immunomodulatory acidic polysaccharide isolated from Cordyceps militaris grown on germinated soybeans. J. Agric. Food Chem. 55, 10194\u201310199 (2007).","journal-title":"J. Agric. Food Chem."}],"updated-by":[{"DOI":"10.1038\/s41598-026-43498-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17982-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:03:13Z","timestamp":1773216193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17982-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17982"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17982-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-43498-5","URL":"https:\/\/doi.org\/10.1038\/s41598-026-43498-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32998"}}